Comprehensive comparison of leading peptide CDMO companies in China Currently, the major peptide drug developers are the world's leading pharmaceutical companies, including NovoNordisk and EliLilly. According to Frost & Sullivan, these two leading peptide drug developers have adopted very different development and production strategies. NovoNordisk manufactures most of its products in-house and tends to avoid CMO/CDMO partnerships. Instead, EliLily utilizes a third-party service provider for
2.
Ankebio: Peptide CDMO business history In 1994, Anhui Ankebio High-Technology Co. was founded; in 2010, the company was recognized as an "Anhui Province Industry-University-Research Joint Demonstration Enterprise"; and in 2013, the company's peptide CDMO business was launched. In 2013, the company's "Dutasteride" was accepted for registration, and Anke Bio broke the ice of chemical innovation.
3.
Ankebio: Peptide CDMO Business Layout and Current Situation --Businesses Layout: business covers a variety of fields The company is a national high-tech enterprise with independent innovation capability mainly in the biomedical industry, the company has long been committed to the research and development, production and sales of biotechnology products, such as cell engineering, genetic engineering, gene detection, precision medicine and other biotechnology products. At present, the company's main business covers biopharmaceuticals, nucleic acid testing products, peptide drugs, modern proprietary Chinese medicines, chemical synthetic drugs and other industrial fields. Shanghai Soho Yiming Pharmaceutical Co.